CD52 and ovarian carcinoma: Targeting of these cells with anti-CCL2 antibody, anti-CSF-IR inhibitors, anti-CD52 antibody, and anti-CD11b antibody for therapy of ovarian cancer has been investigated in preclinical models of ovarian cancer [89,90,91].